Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
General Radiation Oncology
How would you manage a patient with known radiation sensitivity (no known mutation) who developed intractable vomiting after two weeks of treatment of (large field) esophageal treatment?
Decreased dose per fx? Omitting concurrent chemotherapy?
Related Questions
What are your preferred strategies to manage mild to moderate rectal ulceration causing tenesmus and discomfort after chemoradiation for rectal adenocarcinoma?
For patients with peritoneal carcinomatosis and minimal response to neoadjuvant chemotherapy, is there a benefit to palliative cytoreductive surgery followed by whole abdominal radiotherapy?
Is it safe to administer Lu 177 therapies in patients with epidural disease in the spinal canal?
What is your approach to cancer patients who inquire about alternative or complementary treatments?
Do you routinely offer spine SBRT for vertebral metastases regardless of overall patient disease burden or response?
Should we be shrinking rectal cancer fields?
For esophageal adenocarcinoma with extensive associated Barrett's, would you extend your CTV coverage beyond the usual expansions to cover the areas of known Barrett's?
Would you hold CGRP (calcitonin gene-related peptide) monoclonal antibodies such as Eptinezumab-jjmr (Vyepti) before, during, or after lung SBRT?
Do you ever perform adaptive replanning for interfraction tumor volume changes appreciated during a fractionated SRS ( 5 fx) treatment for CNS metastases?
Would you offer adjuvant chemotherapy after SBRT for biopsy proven sub centimeter metastatic pulmonary nodule from rectal cancer?